Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
|
| Operating expenses: | ||||
| Research and development expenses | $ 2,052,233 | $ 2,599,315 | $ 4,372,975 | $ 4,795,306 |
| General and administrative expenses | 1,763,029 | 2,065,331 | 3,391,163 | 4,053,590 |
| Total operating expenses | 3,815,262 | 4,664,646 | 7,764,138 | 8,848,896 |
| Loss from operations | (3,815,262) | (4,664,646) | (7,764,138) | (8,848,896) |
| Other (expense) income: | ||||
| Interest expense | (1,715) | (6,862) | ||
| Interest income | 88,383 | 172 | 132,501 | 508 |
| Australian research and development incentives | 18,048 | 39,766 | 36,649 | 91,009 |
| Change in fair value of warrant liability | (5,157,493) | 102,799 | (9,338,791) | 123,741 |
| Loss on fair value of warrants over proceeds | (12,952) | (12,952) | ||
| Other (expense) income, net | (5,064,014) | 141,022 | (9,182,593) | 208,396 |
| Net loss | (8,879,276) | (4,523,624) | (16,946,731) | (8,640,500) |
| Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ (8,879,276) | $ (4,523,624) | $ (16,946,731) | $ (8,640,500) |
| Net loss per share | ||||
| Net loss per share basic | $ (0.4) | $ (0.35) | $ (0.85) | $ (0.72) |
| Net loss per share diluted | $ (0.4) | $ (0.35) | $ (0.85) | $ (0.72) |
| Weighted average common shares outstanding basic | 22,203,174 | 12,885,134 | 19,906,043 | 11,931,319 |
| Weighted average common shares outstanding diluted | 22,203,174 | 12,885,134 | 19,906,043 | 11,931,319 |
| X | ||||||||||
- Definition Australian research and development incentives. No definition available.
|
| X | ||||||||||
- Definition Gain (loss) fair value of warrants over proceeds. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|